NCT03711877 (COHAIR) is a Phase 3 clinical trial of Scalp cooling system in Primary Breast Cancer, sponsored by Tao OUYANG.

Who is sponsoring NCT03711877?

NCT03711877 is sponsored by Tao OUYANG.

What drugs are being tested in NCT03711877?

Interventions in NCT03711877: Scalp cooling system, Cold cap.

What condition does NCT03711877 study?

NCT03711877 studies Primary Breast Cancer.

Is NCT03711877 still recruiting?

NCT03711877 is currently status unknown. Last updated 29 November 2021.

Last reviewed 2021-11-29 · How we verify

NCT03711877: COHAIR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)

Status unknown Phase 3 Last updated 29 November 2021

What this trial tests

Phase 3 trial testing Scalp cooling system in Primary Breast Cancer in 256 participants. Status unknown.

Timeline

7 March 2019

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Tao OUYANG
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	256
Start date	7 March 2019
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Scalp cooling system
Cold cap

Conditions studied

Primary Breast Cancer — all drugs for Primary Breast Cancer →

Sponsor

Tao OUYANG — full company profile →

Who can join

Adults 18 to 65, female only, with Primary Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase III, single-center, prospective, open-label, randomized,controlled study

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?
Wikramanayake TC, Haberland NI, Akhundlu A, Laboy Nieves A, et al · · 2023 · cited 37× · PMID 37185388 · DOI 10.3390/curroncol30040275
Efficacy of scalp cooling system versus chemical cooling cap in preventing chemotherapy-induced alopecia in breast cancer (COHAIR Study): a prospective randomized trial.
Zhang J, Wang L, He Y, Sun H, et al · · 2026 · PMID 41955993 · DOI 10.1016/j.breast.2026.104784

Verify or expand the search:

Other Tao OUYANG trials

Trials by the same sponsor.

NCT03270007 — Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Can · Phase 4 · unknown
NCT01019616 — Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03711877 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tao OUYANG
Last refreshed: 29 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03711877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing